Georgia
Provider Communications
Anthem clinical criteria updates for specialty pharmacy are available
Access the clinical criteria document information.
Anthem’s prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team. Drugs used for the treatment of Oncology will be managed by AIM Specialty Health® (AIM), a separate company.
- ING-CC-0003 Immunoglobulins
- ING-CC-0011 Ocrevus (ocrelizumab)
- ING-CC-0041 Complement Inhibitors
- ING-CC-0048 Spinraza (nusinersen)
- ING-CC-0062 Tumor Necrosis Factor Antagonists
- ING-CC-0063 Stelara (ustekinumab)
- ING-CC-0071 Entyvio (vedolizumab)
- ING-CC-0121 Gazyva (obinutuzumab)
- ING-CC-0174 Kesimpta (ofatumumab)
- ING-CC-0183 Sogroya (somapacitan-beco)
Featured In:
February 2021 Anthem Provider News - Georgia